Cantor Fitzgerald Downgrades Chinook Therapeutics to Neutral, Announces $40 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Charles Robertson II downgraded Chinook Therapeutics (NASDAQ:KDNY) from Overweight to Neutral and announced a $40 price target.

June 12, 2023 | 4:43 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Chinook Therapeutics (NASDAQ:KDNY) has been downgraded from Overweight to Neutral by Cantor Fitzgerald, with a $40 price target.
The downgrade from Overweight to Neutral by Cantor Fitzgerald indicates a less optimistic outlook for Chinook Therapeutics. This change in rating, along with the announcement of a $40 price target, could lead to a short-term negative impact on the stock price as investors may adjust their positions based on the new rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100